CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate announced today the appointment of Andrew T. Drechsler as chief financial officer (CFO) and Edward J. Arcuri, Ph.D., as chief operations officer (COO). Mr. Drechsler, formerly CFO of Valera Pharmaceuticals, possesses the depth and breadth of financial expertise necessary to successfully guide VaxInnate’s financial operations. Dr. Arcuri, formerly COO and executive vice president, Emergent Biosolutions, Inc., brings extensive, targeted experience in corporate management of the development, manufacture, and commercialization of vaccines, antibodies, and biodefense products. As part of VaxInnate’s executive management team, both will play an integral role in overseeing the financial and corporate operations of the company as it advances the development of its vaccines for human and avian flu, malaria, and other therapeutic indications.
